ANI Pharmaceuticals (NASDAQ:ANIP) Announces Quarterly Earnings Results, Beats Estimates By $0.77 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) posted its quarterly earnings results on Friday. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77, FiscalAI reports. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.ANI Pharmaceuticals’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI raised its 2026 guidance, now targeting $1.08B–$1.14B in revenue, $285M–$300M adjusted EBITDA and $9.19–$9.69 adjusted EPS, driven by rare disease strength.
• Cortrophin Gel revenue grew 42% YoY to $75.1M in Q1, April saw the highest new patient starts since launch, and a 64‑rep commercial expansion into primary care and podiatry is being deployed to accelerate H2/2026 and 2027 growth.
• ANI recognized a $15M upfront fee from an out‑license to Harmony Biosciences, expects an additional $10M in near‑term development milestones (Q2–Q3) and low‑single‑digit royalties on pitolisant (WAKIX), adding immediate cash and future royalty upside.
• Generics continue to fund growth with Q1 generics revenue of $105.4M (up 7%), six new launches YTD and a steady 10–15 launch cadence, while management authorized a new $100M share repurchase program as part of disciplined capital allocation.
• Q1 results were impacted by insurance reverification delays and weather‑related office closures that temporarily depressed early‑quarter Cortrophin volumes and contributed to a lower non‑GAAP gross margin (60.8%), and ILUVIEN still faces ongoing Medicare access challenges.

ANI Pharmaceuticals Stock Down 2.4%

ANIP stock traded down $2.05 during mid-day trading on Friday, hitting $81.86. The stock had a trading volume of 1,218,429 shares, compared to its average volume of 402,621. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a fifty day moving average of $76.82 and a 200 day moving average of $81.01. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 24.36 and a beta of 0.46.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,312 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the transaction, the chief financial officer directly owned 185,543 shares of the company’s stock, valued at $14,008,496.50. This represents a 3.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher Mutz sold 5,323 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $78.02, for a total value of $415,300.46. Following the completion of the transaction, the insider directly owned 84,840 shares in the company, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 27,860 shares of company stock worth $2,111,581. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Twinbeech Capital LP acquired a new position in ANI Pharmaceuticals in the 4th quarter worth about $276,000. Marex Group plc bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth about $258,000. Scientech Research LLC acquired a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at about $257,000. Inceptionr LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $248,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $243,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q1 results materially beat expectations: EPS $2.05 vs. consensus $1.28 and revenue $237.5M vs. $207.6M (revenue +20.5% YoY). Strong top‑ and bottom‑line beats support a re-rating. Read More.
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $9.190–$9.690, above the street consensus (~$8.79), signaling stronger full‑year profitability and underpinning upside to estimates. Read More.
• Neutral Sentiment: Management commentary and details are available in the Q1 earnings call transcript and slide deck for investors who want cadence on product mix, margins, and cadence of revenue. Read More.
• Neutral Sentiment: Analyst and media pieces highlight the beat and guidance raise and walk through key metrics vs. Street and year‑ago results — useful for modeling revisions. Read More.
• Negative Sentiment: Valuation and balance‑sheet points to watch: trailing PE (~25) and debt/equity (~1.11) could limit near‑term upside and increase sensitivity to any guidance misses or margin pressure. Investors should model whether higher FY EPS justifies current multiples. Read More.

Analysts Set New Price Targets

ANIP has been the topic of several recent analyst reports. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Guggenheim upped their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.